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Background: Treatment with the alpha-glucosidase inhibitor (AGI) acarbose is associated with a significant
reduction the risk of cardiovascular events. However, the underlying mechanisms of this effect are unclear. AGIs
were recently suggested to participate in stimulating glucagon-like peptide 1 (GLP-1) secretion. We therefore
examined the effects of a 24-week treatment of acarbose on endogenous GLP-1, nitric oxide (NO) levels, nitric
oxide synthase (NOS) activity, and carotid intima-media thickness (CIMT) in newly diagnosed patients with type 2
diabetes (T2D).
Methods: Blood was drawn from 24 subjects (14 male, 10 female, age: 50.7 ± 7.36 years, BMI: 26.64 ± 3.38 kg/m2,
GHbA1c: 7.00 ± 0.74%) with drug-naïve T2D at 0 and 120 min following a standard mixed meal for the
measurements of active GLP-1, NO and NOS. The CIMT was measured prior to and following 24 weeks of acarbose
monotherapy (mean dose: 268 mg daily).
Results: Following 24 weeks of acarbose treatment, both fasting and postprandial plasma GLP-1 levels were
increased. In patients with increased postprandial GLP-1 levels, serum NO levels and NOS activities were also
significantly increased and were positively related to GLP-1 levels. Although the CIMT was not significantly altered
following treatment with acarbose, a decreased CIMT was negatively correlated with increased GLP-1 levels.
Conclusions: Twenty-four weeks of acarbose monotherapy in newly diagnosed patients with T2D is associated
with significantly increased levels of both fasting and postprandial GLP-1 as well as significantly increased NO levels
and NOS activity for those patients in whom postprandial GLP-1 levels were increased. Therefore, the benefits of
acarbose on cardiovascular risk may be related to its stimulation of GLP-1 secretion.
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Type 2 diabetes (T2D) is known to dramatically increase
the risk of cardiovascular disease, such as angina
pectoris and myocardial infarction, and it is believed that
hyperglycemia itself, especially postprandial hypergly-
cemia, is an independent risk factor for such diseases
[1-4]. The previous studies have shown that treatment
with acarbose, an alpha-glucosidase inhibitor (AGI), is
associated with a significant reduction in cardiovascular* Correspondence: changbc1970@126.com; xfx22081@vip.163.com
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reproduction in any medium, provided the orevents in a population with T2D and impaired glucose
tolerance (IGT) [5,6]. However, the underlying mecha-
nisms of this effect are unclear. Recently, new insights
into the possible actions of acarbose on cardiovascular
risks have been provided by the incretin concept. Fol-
lowing the intake of AGIs, large amounts of undigested
carbohydrates reach the lower portion of the small intes-
tine, which is rich in L-cells that produce glucagon-like
peptide 1 (GLP-1) and therefore stimulate a long-lasting
increased secretion of GLP-1 [7,8]. GLP-1 can elevate
levels of nitric oxide (NO), which is the most important
endothelium-derived vasodilator and has a potent anti-
atherosclerotic effect [9,10] in the coronary effluent fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gests that voglibose (another AGI) can reduce myocardial
infarct size through the stimulation of GLP-1 receptors
and the activation of the phosphoinositide 3-kinase-Akt-
endothelial NOS pathways [12].
To date, the majority of studies have evaluated the
short-term effects of acarbose treatment (up to 2 weeks)
on GLP-1; the long-term effects of AGIs on NO and
NOS in T2D have not been extensively investigated. In
the present study, we aimed to explore whether levels of
serum GLP-1 and NO and NOS activity increase following
chronic (24 weeks) treatment with acarbose monotherapy
in newly diagnosed patients with T2D. We also aimed to
evaluate the effect of acarbose on carotid atherosclerosis
(as defined by carotid intima-media thickness [CIMT]). It
is known that CIMT has an important prognostic value
with respect to the development of both cardiovascular




This was a prospective, observational study of patients
with drug-naive T2D who were commencing acarbose as
a monotherapy. Newly diagnosed patients with T2D (aged
30–70 years) who met the World Health Organization
diagnostic criteria [15] were recruited from the diabetic
outpatient clinic in the Metabolic Disease Hospital of
Tianjin Medical University between October 2011 and
June 2012. The exclusion criteria were glycosylated
hemoglobin Alc (HbA1c >9%), a history of congestive
heart failure (NYHA Class III or IV), or severe hepatic
(serum alanine or aspartate aminotransferase >100 U/L)
or renal disease (estimated creatinine clearance <60 ml/min).
The patients with current malignant disease, inflammatory
bowel disease, those who were pregnant, women who
were breast-feeding and patients who had a history of
major psychiatric disease were also excluded. Lifestyle
intervention was recommended to all of the eligible pa-
tients by the diabetic educator. The patients were also ex-
cluded if their blood glucose was restored to normal
following 1 month of lifestyle intervention. The study
protocol was approved by the Tianjin Medical University
Ethics Committee Review Board and was conducted using
Good Clinical Practice in accordance with the Declaration
of Helsinki. All of the participants provided informed
consent.
Study protocol
On the morning of the first visit (V1), following an over-
night fasting for 12–14 h, the patients were asked to at-
tend the investigational unit. The anthropometric
assessments were performed, including body mass index
(BMI) and blood pressure. The blood was drawn at 0and 120 min following breakfast (the meal was ingested
within 10–15 min) for the measurements of plasma ac-
tive GLP-1, serum insulin NO and NOS activity, and
glycated hemoglobin A1c (GHbA1c). Fasting plasma glu-
cose (FPG) and 2 h postprandial plasma glucose (P2PG)
levels were also determined. The breakfast was a stand-
ard mixed meal that provided approximately 380 kcal,
and the energy load was calculated to be 16.0% fat, 9.5%
protein and 74.5% carbohydrate. The blood samples
were taken and immediately cooled and centrifuged at
4 C. The plasma was stored at −80°C until analysis. The
blood samples for the determination of active GLP-1
were collected into tubes that contained heparin anti-
coagulant and 0.1 mmol/L sitagliptin phosphate (Beijing
HuiKang BoYuan Chemical Tech CO., LTD, Beijing,
China) to prevent degradation by the dipeptidyl peptidase-4
(DPP-4) enzyme. Next, the CIMT was measured for all of
the patients.
Following V1, the patients were commenced on acarbose
tablets (GlucobayW; Bayer AG, Leverkusen, Germany),
beginning at 75 mg daily. The dose was titrated upwards
over a period of 4–18 weeks to the dose that produced
satisfactory metabolic control or to the maximum dose
that was tolerated by the patient. The acarbose tablets
were taken with the first bite of the meal, and the max-
imum given dose was 300 mg daily. The subjects who
experienced gastrointestinal side effects during the
period of upward titration were instructed to return to
the previously tolerated dose for a further 2 weeks and
then to attempt to increase the dosage again if the lower
dose was tolerated. During this time, all of the patients
were instructed to continue with their diet as previously
recommended.
Following V1, the participants were asked to again visit
the investigational site on the 4th (V2), 8th (V3), 12th
(V4), and 18th week (V5) of the study. On these days,
the blood glucose levels were determined, lifestyle advice
was offered (as in routine clinical practice), compliance
with medication was assessed and further dose titration
was recommended, as appropriate. All of the subjects
attended the visits at 6 and 24 weeks following the initi-
ation of acarbose monotherapy, and the procedures that
were described for V1 were repeated. Telephone contact
was maintained with all of the subjects between V1 and V6
to monitor their compliance with the medication and to
offer advice regarding problems with medication tolerance.
Laboratory measurements
Both fasting and 2 h postprandial active GLP-1 levels
[GLP-1 (7–36) and (7–37)] were determined using com-
mercial enzyme-linked immunoassay (ELISA) kits from
Millipore (Billerica, MA, USA). The detection limit of
the ELISA was 2 pmol/L, with an intra-assay coefficient
of variation (CV) of 7.8% ~ 9.9% and interassay CV of
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the nitrate reductase method with the NO Kit (Nanjing
Jiancheng BioEngineering Co., Ltd., Nanjing, China).
The generation of NO was determined by measuring the
release of nitrite (NO2
- and NO3
-), which is the stable oxi-
dation product of NO. The NOS kit (Nanjing Jiancheng
BioEngineering Co., Ltd., Nanjing, China) was used to
measure the activity of NOS in the plasma, in which
NOS produces NO from L-arginine and oxygen in
addition to two iron complexes (the color reagent),
which form a colored material. The absorbance is then
measured at a wavelength of 540 nm, and the extinction
coefficient used to calculate NOS activity. The serum in-
sulin concentration was analyzed using the Roche E170
electrochemiluminescence immunoassay [Elecsys 2012
insulin kit (Ref12017547), Roche Diagnostics GmbH,
Indianapolis, IN, USA].
Carotid ultrasonography measurements
The carotid arteries were assessed using high-resolution
B-mode ultrasonography using GE Logiq 7 ultrasound
with a 10-MHz high-resolution transducer (General
Electric, Wauwatosa, WI, USA). All of the measure-
ments were performed by a single ultrasonographer
using the same equipment and were assessed by a single
reader who was blinded to the study question, patient,
and follow-up time point. A rapid cross-sectional scan-
ning was performed as a first step to pinpoint the loca-
tion of the possible plaques. The scan was begun from
the proximal portion of the common carotid artery
(CCA) toward the bifurcation, followed by a scan of the
internal and then the external carotid arteries. This
process was followed by a longitudinal scanning of the
CCA. A segment of the artery (generally where the vessel
walls were most clearly discerned throughout the record-
ing) was magnified to identify a distinct lumen-intima and
media-adventitia interface. The CIMT was defined as the
distance between the leading edge of the lumen-intima
interface and the leading edge of the media-adventitia
interface. The regions of interest were defined as 1.0 cm
distal to the bifurcation, the bifurcation and 1.0 cm
proximal to the internal carotid artery in both near and
far walls. Next, for each subject, the mean CIMT wasTable 1 Changes in glycemic control and body weight with a
Variable Pre-treatment Post-treatment
GHbA1c (%) 7.00 ± 0.74 6.18 ± 0.51
FPG (mmol/L) 8.31 ± 0.93 7.20 ± 0.85
P2PG (mmol/L) 14.34 ± 2.65 10.10 ± 1.12
Weight (kg) 74.71 ± 12.30 74.96 ± 11.70
BMI (kg/m2) 26.64 ± 3.38 26.64 ± 0.38
Data are expressed as mean ± S.D; HbA1c: glycated haemoglobin A1c; FPG: fasting
mass index.reported as the average of 10 measurements (5 measure-
ments from the right and 5 from the left carotid artery).
Statistical analysis
The data are expressed as the means and the standard
deviation or as numbers and percentages. As the levels
of serum insulin were markedly skewed, natural loga-
rithm -transformed values were used. The differences in
CIMT, anthropometric and laboratory parameters from
baseline to the endpoint were compared using a 2-tailed
paired t-test. Pearson correlation analysis was used
to assess possible relationships between alterations of
plasma GLP-1 and NO levels, CIMT and other laboratory
data. The analyses were performed using SPSS windows
version 17.0, and p < 0.05 was considered to be statisti-
cally significant.
Results
A total of 26 patients entered the trial, 24 (92.3%) of
whom completed the trial. Two patients dropped out
the study (one was not able to tolerate the abdominal
distension and anal exhaust and dropped out at V2, the
other patient was lost of follow up at V3 for unknown
reasons). The mean age of the 24 subjects (14 male, 10
female) was 50.7 ± 7.36 years. The mean dose of
acarbose at visit 6 was 268 mg daily (range: 150–300 mg
daily). Glycemic control improved in all of the patients
following 6 months of acarbose therapy. However, there
was no significant change in body weight or BMI
(Table 1).
Plasma GLP-1 and serum insulin levels
Plasma GLP-1
Following 24 weeks of acarbose monotherapy, the fasting
plasma GLP-1 levels increased from 4.92 ± 0.94 pmol/L
(pre-treatment) to 5.46 ± 1.28 pmol/L (post-treatment)
(P<0.05). The 2 h postprandial GLP-1 levels increased from
5.23 ± 1.26 pmol/L (pre-treatment) to 6.26 ± 1.64 pmol/L
(post-treatment, P<0.05, Figure 1(1)).
Serum insulin
The mean 2 h postprandial serum insulin (natural
logarithm-transformed) levels were significantly reducedcarbose treatment






plasma glucose; P2PG: 2 hour postprandial plasma glucose; BMI: body
Figure 1 Mean values for plasma GLP-1 and serum insulin pre- and post-acarbose treatment. The values of serum insulin was natural
logarithm-transformed; *p < 0.05 for the difference between pre- and post-acarbose treatments.
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0.42 mIU/L vs. pre-treatment 4.72 ± 0.53 mIU/L, p = 0.041).
The mean fasting insulin (natural logarithm-transformed)
levels were marginally reduced following the 24-week treat-
ment period, but this difference was not statistically signifi-
cant (post-treatment: 3.68 ± 0.40 mIU/L vs. pre-treatment:
3.85 ± 0.35 mIU/L, P = 0.064, Figure 1(2)).
Serum NO levels and NOS activity
Both the serum NO levels and NOS activity were mar-
ginally increased following the 24-week acarbose treat-
ment; however, these changes were not statistically
significant (post-treatment NO 49.90 ± 25.07 μmol/L,
NOS activity 32.49 ± 2.34 U/ml vs. pre- treatment NO
47.48 ± 24.18 μmol/L, NOS activity 31.75 ± 2.83 U/ml,
P>0.05, Figure 2(1, 2) A). We further divided the pa-
tients into the following subgroups according to the
observed changes in fasting or 2 h postprandial plasmaFigure 2 Difference of serum nitric oxide, NOS activity and CIMT betw
CIMT: carotid intima-media thickness; A: all of the subjects; B: the subjects w
subjects with increased postprandial GLP-1 following acarbose treatment; *
post-acarbose treatment.GLP-1 levels: fasting GLP-1 increased group (n = 17) vs.
decreased group (n = 7), and postprandial GLP-1 increased
group (n = 18) vs. decreased group (n = 6). We observed
that both the serum NO levels and NOS activities were
significantly increased following acarbose treatment for
those in the postprandial GLP-1 increased subgroup (post-
acarbose NO 50.78 ± 19.28 μmol/L, NOS activity 32.76 ±
2.40 U/ml vs. pre-acarbose NO 46.61 ± 18.49 μmol/L,
NOS activity 31.21 ± 2.50 U/ml, P<0.05, Figure 2(1, 2)C).
No such significant change was observed for those in the
postprandial GLP-1 decreased subgroup (P>0.05, Figure 2
(1, 2)B). There were no significant changes for the fasting
GLP-1 increased or decreased subgroups (P>0.05, data not
shown).
CIMT
The mean CIMT was not significantly different following
24 weeks of acarbose monotherapy (P>0.05, Figure 2 (3)A).een pre- and post-acarbose treatment. NOS: nitric oxide synthase;
ith decreased postprandial GLP-1 following acarbose treatment; C: the
p < 0.05 for the difference between the pre- and
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were not significantly different for either the fasting GLP-
1decreased/increased subgroups (data not shown) or for
the postprandial GLP-1 decreased/increased subgroups
(P>0.05, Figure 2 (3)B, C).The correlation between the changes in GLP-1, NO, CIMT
and other laboratory data with acarbose treatment
Increased values of fasting GLP-1 were negatively corre-
lated with a change in GHbA1c levels (R value: -0.491;
P<0.05). Moreover, increased 2 h postprandial GLP-1 levels
were negatively correlated with the changes of GHbA1c,
FPG and the mean CIMT (R values: -0.636, -0.481
and −0.628, respectively; P<0.05) and positively correlated
with the changes of NO and NOS (R values: 0.452 and
0.561, respectively; P<0.05). The changes in the mean
CIMT were negatively correlated with changes in NO
levels (R value: -0.577; P<0.05) but not with changes in
NOS activity (R value: -0.314; P = 0.135). Furthermore, the
changes in NO levels and NOS activity were positively
correlated (R value: 0.449; P<0.05) (Table 2).Discussion
Our study indicates that chronic acarbose therapy is as-
sociated with a significant increase in both fasting and
postprandial active GLP-1 levels in newly diagnosed pa-
tients with T2D. What’s more, our study provides evi-
dence that postprandial GLP-1 increment after acarbose
treatment is closely correlated with increment of NO
levels and NOS activity and also with reduction of the
mean CIMT. This is, to the best of our knowledge, the
first study to investigate the long term effect of AGIs on
GLP-1, NO secretion, NOS activity and its association
with improved atherosclerosis in newly diagnosed patients
with T2D.Table 2 Correlations between changes in GLP-1, NO, CIMT an
Δfasting GLP-1 Δ2 h postprand
R value P value R value
△Weight −0.143 0.506 0.014
△BMI −0.128 0.550 0.027
△GHbA1c −0.491 0.015 −0.636
△FPG −0.185 0.388 −0.481
△P2PG −0.181 0.398 −0.110
△ln Insulin (0 h) −0.176 0.411 0.145
△ln Insulin (2 h) −0.035 0.871 0.084
△mean CIMT(mm) −0.384 0.064 −0.628
△NO 0.245 0.249 0.452
△NOS 0.268 0.205 0.561
Δ: The change of values following acarbose treatment; ln: natural logarithm -transfo
fasting plasma glucose; P2PG: 2 hour postprandial plasma glucose; CIMT: carotid inEffects of acarbose on plasma GLP-1 and insulin level
We demonstrated that, in newly diagnosed patients with
T2D, chronic acarbose therapy is associated with a sig-
nificant increase in both fasting and postprandial active
GLP-1 concentrations in addition to good glycemic con-
trol, as expected. These results are consistent with other
studies that have reported increased postprandial GLP-1
levels following administration of either (i) following a
single dose of acarbose or following 2 weeks of acarbose
treatment in both normal subjects and those with T2D
[7,8,16,17], or (ii) acarbose in combination with alogliptin
(a DPP-4 inhibitor) [18]. This effect is most likely due to
a reduction in carbohydrate absorption in the proximal
portion of the small bowel, increasing the load of these
nutrients in the distal intestine, where GLP-1 secretion
is greater. Unlike previous studies, we demonstrated this
effect following long-term (24 weeks) therapy, highlighting
yet another important aspect of the glucose-lowering
properties of acarbose among new diagnosed patients with
T2D. In the present study, we first report that fasting
active GLP-1 levels are significantly elevated following
24 weeks of acarbose treatment. As previously reported,
the functional integrity of GLP-1-secreting cells is ser-
iously impaired even in the context of mild diabetes, and
GLP-1 is deficient in patients with T2D [19,20]. Our data
indicate that increased fasting GLP-1 levels are negatively
correlated with changes of GHbA1c and that increased
2 h postprandial GLP-1 levels are negatively correlated
with the observed changes in both GHbA1c and FPG
(Table 2). These results suggest that glycemic control fol-
lowing a 24-week treatment with acarbose may contribute
in part to the restoration of the GLP-1 secretion defect in
newly diagnosed patients with T2D. Previous studies have
focused on the effect of GLP-1 following either a single
dose of acarbose or a brief treatment period (i.e., not
more than 2 weeks), and only changes in postprandiald other laboratory data following acarbose treatment
ial GLP-1 ΔNO ΔNOS
P value R value P value R value P value
0.950 0.024 0.911 0.121 0.574
0.899 0.038 0.861 0.138 0.519
0.001 −0.143 0.504 −0.149 0.488
0.017 0.038 0.859 −0.108 0.617
0.608 0.241 0.256 0.007 0.973
0.498 0.285 0.177 0.363 0.081
0.696 0.135 0.528 0.079 0.713
0.001 −0.577 0.003 −0.314 0.135
0.026 - - 0.449 0.028
0.004 0.449 0.028 - -
rmed values; BMI: body mass index; HbA1c: glycated haemoglobin A1c; FPG:
tima-media thickness; NO: nitric oxide; NOS: nitric oxide synthase.
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that previous studies did not conclusively demonstrate
the relationship between fasting GLP-1 and acarbose
treatment may be due to the short treatment periods
that were tested.
In theory, GLP-1 can stimulate insulin secretion and
inhibit the generation of glucagon. However, our data in-
dicate the level of postprandial insulin is significantly re-
duced (P<0.05) following acarbose treatment and that
fasting insulin levels are marginally reduced (p = 0.064),
even in the patients with increased GLP-1 levels. Fur-
thermore, the increased levels of GLP-1 were not corre-
lated with the change in insulin levels (p > 0.05). It is
known that several factors regulate insulin secretion and
that glucose is the most important nutrient secretagogue.
The delayed digestion of carbohydrates and cleavage of
oligosaccharides by AGIs results in undigested carbohy-
drates reaching the lower portions of the small intestine
and stimulating GLP-1 secretion. This intestinal hor-
mone delays the emptying of the stomach, reduces glu-
cagon secretion, and regulates insulin secretion, which
in fact is dependent on blood glucose concentrations.
This effect may in part explain why long-term treatment
with acarbose results in a reduction in not only post-
prandial but also fasting blood glucose concentrations
[7,21]. Thus, reduced blood glucose concentrations fol-
lowing acarbose treatment may result in (i) markedly
lower stimulation of insulin synthesis and insulin se-
cretion and (ii) decreased insulin resistance-induced
hyperinsulinemia [22].
Effects of acarbose on NO, NOS activity and CIMT
As an endothelium-derived vasodilator, NO has been
demonstrated to play a crucial role in the development
of vascular complications via the regulation of blood
flow and various antiatherosclerotic actions [9,10].
CIMT is a widely accepted indicator of subclinical ath-
erosclerosis burden, with higher values being associated
with an adverse cardiovascular prognosis. Consequently,
CIMT has also been proposed to be a surrogate end
point for therapeutic interventions that aim to lower the
atherosclerotic burden [23,24]. In this study, we also
demonstrated that both serum NO levels and NOS
activity are significantly higher following acarbose treat-
ment in the subjects whose postprandial GLP-1 was
increased (P<0.05). Moreover, the increase in 2 h post-
prandial GLP-1 levels was (i) positively correlated with
changes in NO levels and NOS activity (R values: 0.452
and 0.561, respectively; P<0.05) and (ii) negatively corre-
lated with the change in the mean CIMT (R value −0.669;
P<0.05). It has been reported that GLP-1 participates in
the upregulation of the activity and protein expression
of NOS in human umbilical vein endothelial cells [25]
and improves endothelial dysfunction in patients withT2D and coronary heart disease [26]. What’s more,
serum levels of NO metabolites may be a simple, safe,
convenient and reliable method for the evaluation of
visceral fat accumulation in clinical diagnostic screening
[27]. Several clinical studies have shown GLP-1 analogue
liraglutide, alone or in combination with insulin, has
produced meaningful long-term weight loss, diminished
abdominal obesity and significantly improved eating be-
havior in patients with T2D compared with insulin
treatment alone [28,29], which might be beneficial to
improving endothelial dysfunction.
In a recent animal study, it has reported that orally
administered voglibose, another AGI, protects the myo-
cardium against ischemia–reperfusion injury through
the stimulation of GLP-1 receptors, the activation of
PI3K-Akt endothelial NOS pathways, and the opening of
mitochondrial KATP channels in rabbits after 30 minutes
of coronary occlusion and 48 hours of reperfusion [12].
In the present study, the observed changes in CIMT
were not significantly different pre- and post-acarbose
treatment. In fact, several studies have demonstrated
that AGIs treatment is associated with a significant re-
duction the risk of cardiovascular events in populations
with IGT and T2D [5,6,30]. A recent randomized com-
parable study has shown that AGI, miglitol, can reduce
visceral fat accumulation and cardiovascular risk factors
in subjects with metabolic syndrome [31]. Combination
of miglitol and DPP-4 inhibitor sitagliptin can reduce
postprandial glucose fluctuation and stabilize blood glu-
cose levels [32], which may benefit to delaying atheroscler-
osis [3]. In a subgroup study of the STOPNIDDM trial, for
which the progression of CIMT was the primary objective,
the annual progression of CIMT in the placebo group was
0.014, whereas this value was 0.007 mm (p < 0.01) in the
acarbose group after 3.3 years of follow-up [33]. While we
did not observe that CIMT was significantly decreased
with elevated GLP-1 or NO levels, although the changes
of CIMT were negatively correlated with changes of
fasting, postprandial GLP-1 and NO in the present study
(R values: -0.436, -0.669 and −0.573, respectively; P<0.05).
One possible reason for this result may be due to the brief
period of the study. Twenty-four weeks is perhaps too
short a period over which to observe changes in CIMT.Study limitations
The present study has several limitations. First, it is a
non-randomized controlled study. Having a placebo arm
may have strengthened our study further. What’s more,
only 24 patients finished in the study and the sample size
is small, which might be a reason that we didn’t observe
significant change of NO level and NOS activity although
postprandial GLP-1 increment is closely correlated with
increment of NO levels and NOS activity after 24-week
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trolled study is needed.
Conclusions
24 weeks of acarbose treatment in newly diagnosed
patients with T2D is associated with increased levels of
both fasting and postprandial GLP-1. Moreover, increased
GLP-1 levels increase NO secretion and NOS activity,
potentially explaining the beneficial role of acarbose in
preventing cardiovascular disease in these patients.
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